Clinical Trial Update: A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Brentuximab Vedotin in Hodgkin lymphoma patients unsuitable for chemotherapy due to age, frailty, or comorbidity; the study is reported…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Adcetris) (brentuximab vedotin)

Snippet

Sponsor: University of Birmingham | Conditions: Hodgkin Disease | Phase 2 | Status: COMPLETED